BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion
Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, has released a business status update. According to the update, which outlines key 2024 progress, the company continues to move forward on developing and advancing its lead candidate, ONP-002, for the treatment of concussion. Specifically, the update noted that phase 2 human trials are slated to begin in the fourth quarter of this year. In addition to preparing for the upcoming phase 2 clinical trials, highlights of the report included the stability of ONP-002 across a wide temperature range, improvements in drug…
